Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CFP 37849 and CGP 39551 in genetically epilepsy-prone rats

Brain Research

Volumn 734, Issue 1-2, 1996, Pages 91-97

  De Sarro, Giovambattista ^a,d   De Sarro, Angela ^b   Ammendola, Domenico ^b   Patel, Smita ^c  

^a UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^d Policlinico Mater Domini   (Italy)

Author keywords

Anticonvulsant; Audiogenic seizure; CGP 37849; CGP 3955I; Epilepsy; Excitatory amino acid antagonist; Genetically epilepsy prone rat; Tolerance

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; ANTICONVULSIVE AGENT; CFP 37849; GLUTAMATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; EPILEPSY; LOCOMOTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SEIZURE;

EID: 0030599169     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00616-6     Document Type: Article

References (47)

1. [1] Belleville, R.E. and Fraser, H.F., Tolerance to some effects of barbiturates, J. Pharmacol. Exp. Ther., 120 (1957) 469-474.
2. [2] Boast, C.A., Pastor, G., Gerhardt, S.C., Hall, N.R. and Liebman, J.M., Behavioral tolerance and sensitization to CGS 19755, a competitive N-methyl-D-aspartate antagonist, J. Pharmacol. Exp. Ther., 147 (1988) 556-561.
3. [3] Cain, D.P., Desorough, K.A. and Mckitric, D.J., Retardation of amygdala kindling by antagonism of NMD-aspartate and muscarinic cholinergic receptors: evidence for the summation of excitatory mechanisms in kindling, Exp. Neurol., 100 (1988) 179-187.
4. [4] Chapman, A.G., Anticonvulsant activity of excitatory amino acid antagonists. In E.A. Cavalheiro, J. Lehmann and L. Turski (Eds.), Frontiers in Excitatory Amino Acid Research, Alan Liss, New York, 1988, pp. 203-210.
5. [5] Chapman, A.G., Graham, J.L. and Meldrum, B.S., Anticonvulsant action of a novel competitive NMDA-antagonist, CGP 39551, in BDA/2 mice, J. Cereb. Blood Flow Metab., 9 (1989) S309.
6. [6] Chapman, A.G., Graham J.L. and Meldrum, B.S., Potent oral anticonvulsant action of CPP and CPPene in DBA/2 mice, Eur. J. Pharmacol., 178 (1990) 97-99.
7. [7] Chapman, A.G., Meldrum, B.S., Nanji, N. and Watkins, J.C., Anticonvulsant action and biochemical effects in DBA/2 mice of CPP (3-((±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate), a novel N-methyl-D-aspartate antagonist, Eur. J. Pharmacol., 139 (1987) 91-96.
8. [8] Collingridge, G.L. and Bliss, T.V.P., NMDA receptor: their role in long-term potentiation, Trends Neurosci., 10 (1987) 288-294.
9. [9] Cotman, C.W., Monaghan, D.T. and Ganong, A.H., Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity, Ann. Rev. Neurosci., 11 (1988) 61-80.
10. [10] Croucher, M.J., Bradford, H.F., Sunter, D.C. and Watkins, J.C., Inhibition of the development of electrical kindling of the prepyriform cortex by daily focal injections of excitatory amino acid antagonists, Eur. J. Pharmacol., 152 (1988) 29-38.
11. [11] Croucher, M.J., Collins, J.F. and Meldrum, B.S., Anticonvulsant action of excitatory amino acid antagonists, Science, 216 (1982) 899-901.
12. [12] Czuczwar, S.J. and Meldrum, B.S., Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid, Eur. J. Pharmacol., 83 (1982) 335-338.
13. [13] De Sarro, G.B. and De Sarro, A., Anticonvulsant activity of competitive antagonists of NMDA receptor in genetically epilepsy-prone rats, Eur. J. Pharmacol., 215 (1992) 221-229.
14. [14] De Sarro, G.B. and De Sarro, A., Anticonvulsant properties of non-competitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene, Neuropharmacology, 32 (1993) 51-58.
15. [15] De Sarro, G.B., De Sarro, A., Federico, F. and Meldrum, B.S., Anticonvulsant properties of some calcium antagonists on sound-induced seizures in genetically epilepsy prone rats, Gen. Pharmacol., 21 (1990) 769-778.
16. [16] De Sarro, G.B., Meldrum, B.S. and Reavill, C., Anticonvulsant action of 2-amino-7-phosphoeptanoic acid in the substantia nigra, Eur. J. Pharmacol., 106 (1984) 175-179.
17. [17] De Sarro, G.B., Patel, S. and Meldrum, B.S., Anticonvulsant action of a kainate antagonist γ-glutamylaminomethylsulphonic acid (GAMS) injected focally into the substantia nigra and entopeduncular nucleus, Eur. J. Pharmacol., 132 (1987) 229-236.
18. [18] De Sarro, G.B., Rotiroti, D., Gratteri, S., Sinopoli, S. Iuliano, M. and De Sarro, A., Tolerance to anticonvulsant effects of clobazam, diazepam and clonazepam in genetically epilepsy prone rats. In G. Biggio, A. Concas and E. Costa (Eds.), GABAergic Synaptic Transmission, Advances in Biochemical Pharmacology Vol. 47, Raven Press, New York, 1992, pp. 249-254.
19. [19] Domino, E.F. and Luby, E.D., Abnormal mental states induced by phencyclidine as a model of schizophrenia. In E.F. Domino (Ed.), PCP (Phencyclidine): Historical and Current Perspectives, NPP Books, Ann Arbor, 1981, pp. 401-418.
20. [20] Dunham, N.W. and Miya, T.S., A note on a simple apparatus for detecting neurological deficit in rats and mice, J. Am. Pharm. Assoc., 46 (1957) 208-209.
21. [21] Fagg, G.E., Olpe, H.R., Pozza, M.F., Baud, J., Steinmann, M., Schmutz, M., Portet, C., Baumann, P., Thedinga, K., Bittiger, H., Allgeier, H., Heckendorn, R., Angst, C., Brundish, D. and Dingwall, J.G., CGP 37849 and CGP 39551: novel and potent competitive W-methyl-D-aspartate receptor antagonists with oral activity, Br. J. Pharmacol., 101 (1990) 791-797.
22. [22] Ferkany, J.W., Borosky, S.A., Clissold, D.B. and Pontecorvo, M.J., Dextromethorphan inhibits NMDA-induced convulsions, Eur. J. Pharmacol., 151 (1988) 151-154.
23. [23] File, S.E., Tolerance to the anti-pentylenetetrazole effects of diazepam in the mouse, Psychopharmacology, 79 (1983) 284-286.
24. [24] Gastaut, H. and Low, M.D., Antiepileptic properties of clobazam, a 1,5 benzodiazepine in man, Epilepsia, 20 (1979) 437-446.
25. [25] Holmes, K.H., Bilkey, D.K., Laverty, R. and Goddard, G.V., The N-methyl-D-aspartate antagonists aminophosphonovalerate and carboxypiperazinephosphonate retard the development and expression of kindled seizures, Brain Res., 506 (1990) 227-235.
26. [26] Jobe, P.C., Pharmacology of audiogenic seizures. In R.D. Brown and E. A. Daigneault (Eds.), Pharmacology of Hearing. Experiment and Clinical Bases, John Wiley, New York, 1981, pp. 271-304.
27. [27] Leander, J.D., Rathbun, R.C. and Zimmerman, D.M., Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D-aspartic acid antagonism, Brain Res., 454 (1988) 368-372.
28. [28] Lehmann, J., Hutchinson, A.J., McPherson, S.E., Mondadori, C., Schmutz, M., Siunton, C.M., Tsai, C., Murphy, D.E., Steel, D.J., Williams, M., Cheney, D.L. and Wood, P.L., CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist, J. Pharmacol. Exp. Ther., 246 (1988) 65-75.
29. [29] Lehmann J., Schneider, J., McPherson, S., Murphy, D.E., Bernard, P., Tsai, C., Bennet, D.A., Pastor, G., Steel, D.J., Boehm, C., Cheney, D.L., Liebman, J.M., Williams, M. and Wood, P.L., CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo, J. Pharmacol. Exp. Ther., 240 (1987) 737-746.
30. [30] Lippa, A.S. and Regan, B., Additional studies on the importance of glycine and GABA in mediating the actions of benzodiazepines, Life Sci., 21 (1977) 1779-1784.
31. [31] Litchfield, J.T. and Wilcoxon, F., A simplifield method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther., 96 (1949) 99-113.
32. [32] Lodge, D., Aram, J.A., Church, J., Davies, S.N., Martin, D., Millar, J. and Zeman, S., Sigma opiates and excitatory amino acids. In E.D. Lodge (Ed.), Excitatory Amino Acids in Health and Disease, John Wiley, Chichester, 1988, pp. 237-259.
33. [33] Löscher, W., Nolting, B. and Hönack, D., Evaluation of CPP, a selective NMDA antagonists, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital, Eur. J. Pharmacol., 152 (1988) 9-17.
34. [34] Meldrum, B.S., Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters, Clin. Sci., 68 (1985) 113-122.
35. [35] Meldrum, B.S., Millan, M., Patel, S. and De Sarro, G.B., Anti-epileptic effects of focal micro-injection of excitatory amino acid antagonists, J. Neural. Trans., 72 (1988) 191-200.
36. [36] Morris, R.G.M., Anderson, E., Lynch, G.S. and Baudry, M., Selective impairment of learning and blockade of long-term potentiation by and N-methyl-D-aspartate receptor antagonist, Nature, 319 (1986) 774-776.
37. [37] Nevins, M.E. and Arnolde, S.M., A comparison of the anticonvulsant effects of competitive and non-competitive antagonists of the N-methyl-D-aspartate receptor. Brain Res., 503 (1989) 1-4.
38. [38] Oxley, J., Tolerance to the antiepileptic effect of clobazam in patients with severe epilepsy. In W.P. Koella, H.H. Frey, W. Froscher and H. Meinardi (Eds.), Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs, Raven Press, New York, 1986, pp. 119-125.
39. [39] Patel, S., De Sarro, G.B. and Meldrum, B.S., Regulation of seizure threshold by excitatory amino acids in the striatum and entopeduncular nucleus of rats, Neuroscience, 23 (1988) 837-850.
40. [40] Schmidt, D., Loscher, W. and Oxley, J., Clinical development of benzodiazepines and other antiepileptic drugs for intractable epilepsy. In D. Schmidt and P.L. Morselli (Eds.), Intractable Epilepsy, Raven Press, New York, 1986, pp. 219-225.
41. [41] Schmidt, D., Rohde, M., Wolf, P. and Roeder-Vanner, U., Tolerance to the antiepileptic effect of clobazam. In W.P. Koella, H.H. Frey, W. Froescher, H. Meinardi (Eds.), Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs, Raven Press, New York, 1986, pp. 109-115.
42. [42] Schmutz, M., Portet, C., Jeker, A., Klebs, K., Vassout, A., Allgeier, H., Heckendorn, R., Fagg, G.E., Olpe, H.R. and van Riezen, H. (Eds.), The competive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents, Arch. Pharmacol., 342 (1990) 61-66.
43. [43] Smith, S. and Chapman, A.G., Acute and chronic anticonvulsant effects of D(-)CPPene in genetically epilepsy prone rats, Epilepsy Res., 15 (1993) 193-199.
44. [44] Tricklebank, M.D., Singh, L., Oles, L.J., Preston, C. and Iversen, S.D., The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor, Eur. J. Pharmacol., 167 (1989) 127-135.
45. [45] Turski, L., Klokgether, T., Sontag, K.H., Herrling, P.L. and Watkins, J.F., Muscle relaxant activity of 3-((±)-2-carboxy-piperazin-4-yl)-propyl-1-phosphonic acid, a novel N-methyl-D-aspartate antagonist, in rodents, Neurosci. Lett., 73 (1987) 143-148.
46. [46] Turski, L., Klockgether, T., Turski, W.A., Ikonomidou, C., Schwarz, M. and Sontag, K.H., Muscle relaxant action of excitatory amino acid antagonist: sites of action. In E.A. Cavalheiro, J. Lehman and L. Turski (Eds.), Frontiers in Excitatory Amino Acid Research, Alan Liss, New York, 1988, pp. 343-350.
47. [47] Turski, L., Schwarz, M., Turski, W.A., Klokgether, T., Sontag, K.H. and Collins, J.F., Muscle relaxant action of excitatory amino acid antagonist, Neurosci. Lett., 53 (1985) 321-326.